Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06799533 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 11 | PfizerINDUSTRY | 5 | Mar 18, 2026 | clinicaltrials |
| NCT06804824 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 220 | Vividion Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT07479667 | An Antibody-armored Dendritic Cell in Patients With Solid Tumors(dendritic cell) | recruiting | Phase 1 | 8 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06056024 | A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus | completed | Phase 1 | 47 | Boehringer IngelheimINDUSTRY | 4 | Mar 17, 2026 | clinicaltrials |
| NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06540066 | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 35 | BeiGeneINDUSTRY | 3 | Mar 16, 2026 | clinicaltrials |
| NCT05935098 | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | terminated | Phase 1 | 99 | BeiGeneINDUSTRY | 5 | Mar 13, 2026 | clinicaltrials |
| NCT06391918 | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 37 | GenVivo, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 990 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04261413 | Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 16 | RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.INDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07417189 | A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) | recruiting | Phase 1 / Phase 2 | 401 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05735366 | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Chugai PharmaceuticalINDUSTRY | 2 | Mar 10, 2026 | clinicaltrials |
| NCT05781048 | A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462442 | Study of QLS5308 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 192 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 10, 2026 | clinicaltrials |
| NCT04723810 | TumorGlow Intraoperative Molecular Imaging (IMI) | recruiting | Phase 1 / Phase 2 | 500 | University of PennsylvaniaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07069062 | A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 261 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04695327 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy(TUNIMO) | completed | Phase 1 | 32 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors(MAST) | terminated | Phase 1 | 66 | Imugene LimitedINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT05661201 | NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors | recruiting | Phase 1 | 24 | Georgetown UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06063317 | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)(OASIS) | terminated | Phase 1 | 25 | Imugene LimitedINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | terminated | Phase 1 | 29 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06667960 | Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 255 | Salubris Biotherapeutics IncINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07222631 | SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 48 | University of California, San DiegoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02617277 | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | completed | Phase 1 | 56 | AstraZenecaINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06424665 | A Study of FZ-AD005 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 162 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07304128 | A Study of PLB-002 in Advanced Solid Tumors | recruiting | Phase 1 | 100 | Primelink BioTherapeitics(ShenZhen) LimitedINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446816 | A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181 | recruiting | Phase 1 | 24 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | completed | Phase 1 / Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06612645 | Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors(CMD03) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06715124 | QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | active not recruiting | Phase 1 | 237 | Quanta TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07269080 | STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study(STM-06) | recruiting | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03833700 | A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | active not recruiting | Phase 1 | 70 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04294628 | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | active not recruiting | Phase 1 | 123 | Replimune, Inc.INDUSTRY | 5 | Feb 27, 2026 | clinicaltrials |
| NCT05914376 | Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors | active not recruiting | Phase 1 | 24 | Hangzhou Converd Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07279428 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | recruiting | Phase 1 | 200 | Nuvalent Inc.INDUSTRY | 3 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07434609 | Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 150 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2026source: clinicaltrials